The value of commercial clinical trials
One of the main messages outlined in the ‘Lord O’Shaughnessy review on commercial clinical trials’ was the economic and financial value to the UK. The review's own research showed that…
One of the main messages outlined in the ‘Lord O’Shaughnessy review on commercial clinical trials’ was the economic and financial value to the UK. The review's own research showed that…
Publication of today's long term NHS Workforce Plan marks a milestone for two reasons. Firstly, because its content is genuinely reforming - significant commitments with the potential to address critical…
Starting a healthcare business in the UK can feel like trying to navigate a maze while juggling. It’s a challenge but it’s not impossible. With the right approach and understanding…
In November 2022, the Secretary of State for Health and Social Care, Steve Barclay, commissioned Former Health Secretary Rt Hon Patricia Hewitt to conduct an independent review into Integrated Care…
In January 2023, Newmarket Strategy were part of a UK delegation of health leaders who visited the global conference Arab Health in Dubai to learn more about new cutting-edge innovations…
Reflections from Manager Dr Nick Burstow on the delivery plan for recovering urgent and emergency care services It was during the second wave of the pandemic that I first…
The latest delivery plan for recovering urgent and emergency care services, co-published by NHS England and the Department for Health & Social Care (DHSC) and announced by the Prime Minister…
Everywhere this author looks, it is clear: the NHS is in crisis. Waiting times have skyrocketedi, ambulance delays are the worst on recordii, and NHS staff are ‘petrified’ of how…
Lord James O’Shaughnessy, Senior Partner at Newmarket Strategy, and Piers Ricketts, CEO of Eastern AHSN, reflect on a recent conversation A few weeks ago we jointly hosted a webinar,…
With the ground-breaking approval last month of the life-extending drug combination, palbociclib (a blockbuster monotherapy) with fulvestrant, for patients with advanced breast cancer,[1] as well as other recent combination therapy…